Zuventus Healthcare Limited, Mumbai
Alhad Mahajani has extensive work experience in the pharmaceutical industry. Alhad began their career in 1992 as a Medical Representative at Lupin and quickly proved himself as the highest productive representative for Softovac in Maharashtra. Alhad then worked at Charak Pharma Pvt. Ltd. as a Product Executive, where they successfully managed and launched M2-Tone tablets. In 1996, Mahajani joined Glenmark Pharmaceuticals Ltd. as a Product Executive before moving to Blue Cross Laboratories Ltd., where they held the positions of Product Manager and Senior Product Manager, responsible for marketing Meftal and Tus-Q. Alhad achieved more than 20% growth for the brand through strategic positioning and promotion. Mahajani joined Alkem Laboratories Ltd. in 1999 as a Group Product Manager and was instrumental in expanding the company into new segments, introducing 10 new brands in cardiac and diabetic segments. After 2 years, they moved to Wanbury Limited as a Marketing Manager and was responsible for significantly increasing market share and turnover through the launch of 17 new brands across various categories. In 2002, Mahajani joined Zuventus Healthcare Ltd. as the VP of Marketing and played a crucial role in the company's growth. Alhad is currently an Angel Investor at Inflection Point Ventures and also serves as a Visiting Faculty at the University Institute of Chemical Technology.
Alhad Mahajani completed their Doctor of Business Administration (DBA) degree from SP Jain School of Global Management in Dubai, Mumbai, Singapore, and Sydney, graduating in 2023. Prior to this, they attended the Indian Institute of Management Ahmedabad for the 3TP: Senior Leaders' Programme in 2020. In 2019, they participated in the Executive Development Programme in Strategic Management at the Indian Institute of Management Kashipur. Before pursuing these executive programs, they obtained a Master of Business Administration (MBA) with a specialization in Marketing from ITM Group of Institutions between 1993 and 1995. Their undergraduate degree is a Bachelor of Pharmacy (BPharm) from Poona College of Pharmacy, Pune, completed from 1988 to 1992. Alhad completed their high school education at Don Bosco High School in Borivali from 1980 to 1986. Additionally, they have obtained several certifications related to Digital Transformation, Sustainable Business Strategy, Leading Organizations & Change, and Leading From the Emerging Future from reputable institutions like SPJIMR - Executive Education, Harvard Business School, and MIT Sloan School of Management.
Zuventus Healthcare Limited, Mumbai
The journey of Zuventus Healthcare began in 2002 when a visionary with pharmaceutical expertise instituted a pharma venture for developing therapeutic products that would improve people’s health, aid faster recovery, and empower them to lead quality lives. The mainstays of this concept were – paramount emphasis on quality, ethics, compliance to standards in operations, and making affordable medicines. A concept whose foundations were as strong as these and which was driven by an unshakeable conviction to care for life inevitably reaches its goal. From 400 employees in 2002 to 3000+ employees today, Zuventus Healthcare is the fastest growing pharma company in India with effective and robust product lines covering a range of therapeutic segments including anti-infectives, vitamins/minerals/nutrients, respiratory generics, gastrointestinal, cardiac, gynaecological, pain/analgesic, antidiabetic, cephalosporins and more available in multiple dosages forms such as tablets, capsules, injectables, and liquids. Zuventus has strong manufacturing capabilities based in Jammu, Sikkim, and Bengaluru as well as a DSIR-approved, advanced formulation R & D centre in Pune. Zuventus’s stupendous growth is evident from the fact that – the company crossed the “100-crore” mark in April 2006, the “200-crore” mark in September 2007 and were quick to achieve a turnover of 2000 crores in 20 years. Today, the company is ranked 7th in the directly covered market and overall ranked 23rd amongst the leading pharmaceutical companies in India. As we propel ahead, we will continue to push the boundaries, invest in research and technology to develop drugs and vaccines for improving patients’ wellbeing.